NCT06960382View on ClinicalTrials.gov

Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Asthma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 26, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2028

Conditions
Allergic RhinitisAllergic Asthma
Interventions
DRUG

ALUTARD SQ® Felis domesticus

The drug is approved for use in Switzerland for subcutaneous injections. I this study, we will test the intralympahtic injection

Trial Locations (1)

8091

University Hospital Zurich, Zurich

All Listed Sponsors
lead

University of Zurich

OTHER

NCT06960382 - Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Asthma | Biotech Hunter | Biotech Hunter